

Day 1: Thursday, February 6, 2025

Opening & keynote lecture 1 - 12:30 - 13:15 Room Schweitzer

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)

Carl June (United States)  
Keynote Lecture

Acute and chronic leukemias - 13:15 - 14:15 Room Schweitzer

Chairs: Ulrich Jäger (Austria) & Mette Hazenberg (The Netherlands)

Lessons learnt from AML  
Nela Klein Gonzalez (Spain)

CAR-T cells for CLL: When? for whom?  
Tanya Siddiqui (United States)

Adult ALL  
Claire Roddie (United Kingdom)

Pediatric ALL  
Peter Bader (Germany)

Coffee break - 14:15 - 14:45

Translational I: New frontiers and innovations - 14:45 - 16:15 Room Schweitzer

Chairs: Melita Irving (Switzerland) & Stanley Riddell (United States)

Special lecture  
Stanley Riddel (United States)

In vivo site-specific engineering to reprogram T cells  
Will Nyberg (Sweden)

Pooled CRISPR Screens: Reprogramming Therapeutic T Cells  
Franzisca Blaeschke (Germany)

Modulating signaling activities to enhance CAR T cell potency  
Judith Feucht (Germany)

Patient in focus: Delving into CAR T-Cell therapy accessibility challenges - 14:45 - 16:15 Room Cassin

Chairs: Jana Pelouchova (Czechia) & Natacha Bolaños (Spain)

Economic and organizational impact of the introduction of CAR-T-cell therapy  
Beatrice Casadei (Italy)

Hospital exemption as a route for patient access to CAR-T therapy, enabling on-site manufacturing with greater flexibility and reduced costs for sustainable access  
Manel Juan (Spain)

Recommendations for Health System Solutions  
Liora Bowers (France)

Satellite symposium by Bristol Myers Squibb: Maximizing Patient Outcomes: Latest Advances in LBCL 2L and Early-Line RRMM - 16:30 - 17:15 Room Schweitzer

Welcome  
Luc-Matthieu Fornecker (France)

What's new in LBCL 2L CAR T?  
Roch Houot (France)

Latest Updates in Early-Line RRMM immunotherapy  
Paula Rodríguez-Otero (Spain)

Q&A and adjourn  
All faculty

Coffee break - 17:15 - 17:30

Chairs: Julio Delgado (Spain) & Stephan Mielke (Sweden)

**CD19-DIRECTED CAR T CELL THERAPY IN 5 PATIENTS WITH REFRACTORY MULTIPLE SCLEROSIS**  
Johanna Richter (Germany)

**RAPCABTAGENE AUTOLEUCEL (YTB323) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): UPDATED RESULTS FROM A PHASE II CLINICAL TRIAL**  
Pere Barba (Spain)

**REDUCTION IN EXTRAFOLLICULAR B CELL RESPONSES IN SLE PATIENTS AFTER CAR-T CELL THERAPY**  
Danae-Mona Nöthling (Germany)

**THERAPY RELATED MYELOID NEOPLASM FOLLOWING CD19 DIRECTED CAR T CELLS FOR PATIENTS WITH B-CELL LYMPHOMA**  
Nicolas Gazeau (France)

Chairs: Ulrike Köhl (Germany) & Ulrich Jäger (Austria)

**AUTOCRINE GLUCOCORTICOID SIGNALING IN HORMONALLY ACTIVE CANCERS INDUCES ANTIGEN EXPRESSION FOR CAR-T CELL THERAPY**  
Marc Philipp Schauer (Germany)

**IDENTIFICATION OF TUMOR-DERIVED MICRORNA125A AS A CATALYST FOR CAR-T CELL DYSFUNCTION IN B CELL MALIGNANCIES**  
Olivia Sirpilla (United States)

**CAFFEINE-REGULATED MOLECULAR SWITCHES FOR FUNCTIONAL CONTROL OF CAR-T CELLS**  
Elise Sylvander (Austria)

**DISTINCT PREFERENCES OF CD8+ AND CD4+ CAR-T CELLS FOR TRANSCRIPTION FACTOR ENHANCEMENT**  
Fabian Freitag (Germany)

**CTLA-4-BASED ACTIVATION INDUCIBLE COSTIMULATORY RECEPTORS BESTOW CAR-T CELLS WITH SAFE, TUMOR-RESTRICTED, MULTI-TARGETING AND IMPROVED FUNCTIONAL FITNESS**  
Afroditi Katsarou (The Netherlands)

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)

**Keynote Lecture**  
Monica Casucci (Italy)

Day 2: Friday, February 7, 2025

Clinical management session - 08:30 - 09:30Room Schweitzer

Chair: Ibrahim Yakoub-Agha (France)

Secondary malignancies after CAR T  
Fabio Ciceri (Italy)

Infection complication after CAR T  
Lidia Gil (Poland)

Cardiac complication after CAR T  
Roni Shouval (United States)

European projects and networks - 08:30 - 09:30Room Cassin

Chair: Jürgen Kuball (The Netherlands)

GoCART  
Christian Chabannon (France)

T-FITNESS  
Luca Gattinoni (Germany)

JOIN4ATMP  
Annette Künkele (Germany)

AIDPATH  
Carmen Sanges (Germany)

Nurses Track - Session 1 - 08:30 - 09:30Room Curie

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Opening comments  
Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Keynote lecture  
Anna Sureda (Spain)

Keynote: Equity and access to CART  
Nico Gagelmann (Germany)

Solid tumors - 09:30 - 10:30Room Schweitzer

Chair: Annette Künkele (Germany)

Special speaker: CAR T for Solid Tumors/Glioblastoma study  
Michael Hudecek (Germany)

Treatment of solid tumors with NKG2D-based CAR T-cells  
John Maher (United Kingdom)

Glioblastoma  
Denis Migliorni (Switzerland)

Next-generation CAR-T cells for solid tumors and hematological malignancies  
Sonia Guedan (Spain)

Nurses Track - Session 2: Fundamentals of cell and gene therapy - 09:30 - 10:30Room Curie

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Prehabilitation and rehabilitation - Optimising function during CAR T  
Orla McCourt (United Kingdom)

Acute toxicity management  
Ruth Clout (United Kingdom)

Late complications  
Edoardo Campodonico (Italy)

Q&A  
All speakers

Coffee break - 10:30 - 11:00

Tech Talk by Kyverna: Development of Ingenui-T, a Rapid Autologous CAR T-Manufacturing Solution Using Whole Blood, for Treatment of Autoimmune Diseases - 10:45 - 10:55

Gallerie Schweitzer

Karen Walker (United States)

Manufacturing and regulatory aspects - 11:00 - 12:30Room Schweitzer

Chair: Ulrike Köhl (Germany)

GMP lentiviral manufacturing

Hugo Calderón (Spain)

Regulatory aspect

Attila Sebe (Germany)

Facilitating CAR T cell manufacturing: short-term CAR T cells and in vivo CAR delivery are moving into clinics

Christian Buchholtz (Germany)

Reimbursement of CAR T cells

Julio Delgado (Spain)

Panel discussion

All speakers

Clinical cases session - 11:00 - 12:00Room Cassin

Chairs: Nico Gagelmann (Germany) & Koray Yalcin (Türkiye)

CAR T for autoimmune diseases

Fabian Müller (Germany)

Allogeneic CAR T

Reuben Benjamin (United Kingdom)

Gene therapy for hemoglobinopathies

Marina Cavazzana (France)

Nurses Track - Session 3: Fundamentals of cell and gene therapy - 11:00 - 12:30Room Curie

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Update CART in hemato-oncology

Annalisa Ruggeri (Italy)

CART in autoimmune disease indications

Raffaella Greco (Italy)

Bispecifics - where do they fit?

Jeremy Deuel (Switzerland)

Gene therapy in hemoglobinopathy

Hilda Mekelenkamp (The Netherlands)

Lunch - 12:30 - 13:30

Satellite Symposium by Gilead: Is a Cure in R/R Lymphomas on the Horizon? Insights from ASH2024 - 13:00 - 13:45

Room Schweitzer

Chair: Roch Houot (France)

Welcome and introduction

Roch Houot (France)

CAR T in practice: insights and implications from real-world data

Roch Houot (France)

Optimising Patient outcomes in CAR T care

Victoria Campbell (United Kingdom)

Are we moving towards a cure in R/R lymphoma?

Abdulwahab Albabtain (Saudi Arabia)

Wrap up and Q&A

All faculty

Chair: Maik Luu (Germany)

- Mitochondrial transfer for adoptive T cell therapy**  
Luca Gattinoni (Germany)
- Targeting metabolites / metabolic reprogramming**  
Mattias Wenes (Switzerland)
- Engineered T cells in the tumor microenvironment**  
Melita Irving (Switzerland)
- Models for CRS, ICANs, ICAHT**  
Robert Zeiser (Germany)

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

- The importance of outcome reporting**  
Antonia Mueller (Austria)
- Remote monitoring CARAMA**  
Fanny Colin (France)
- PPIE & CART service evaluation**  
Britt Snoek (The Netherlands)
- The last bridge - How patients experience CAR T-cell therapy and possible fields of action for nurses in the course of the treatment**  
Verena Leinemann (Austria)

- Alberto Vasconles (Switzerland)
- Premal Kamdar (United States)
- John Harkins (United States)

- Welcome and introduction to CAR-T in MM**  
Hermann Einsele (Germany)
- Selecting CAR-T in clinical practice: right patient, right time**  
Sonja Zweegman (The Netherlands)
- Using CAR-T in clinical practice: maximising benefit**  
Max Topp (Germany)
- Audience Q&A**  
All faculty

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)

- Keynote Lecture**  
Martin Pule (United Kingdom)

Chairs: Raffaella Greco (Italy) & Annalisa Ruggeri (Italy)

- iPSC-derived CAR T**  
Sjoukje van der Stegen (United States)
- CAR-MSK**  
Saad Kenderian (United States)
- CAR-treg**  
Chiara Bonini (Italy)
- Round table**  
All speakers

Chair: Carmen Sanges (Germany) & Monica Casucci (Italy)

Opening Remark

Michael Hudecek (Germany) & Monica Casucci (Italy)

Immune-Related Adverse Outcome Pathways (irAOPs) and Safety Assessment in Cellular Therapies

Miriam Alb (Germany)

Preclinical Models in T2EVOLVE

Emmanuel Donnadieu (France) & Patricia Perez (Spain)

Panel Discussion: Shaping the Future of Preclinical Models:  
Data Extrapolation, Platform Technologies, and Clinical Translation in ATMPs

Emmanuel Donnadieu (UNITC), Miriam Alb (ImSavar), Antonio Müller (JOIN4ATMP), Ulrike Philippar (Janssen WP4 co-leader), Jacquelyn Awigena-Cook (BMS, T2EVOLVE regulatory board representative)

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

LONGITUDINAL PATIENT REPORTED OUTCOMES (PROS) OF CAR T-CELL THERAPY AND THEIR IMPACT ON SURVIVAL

Anna Spanjaart (The Netherlands)

AN EXAMINATION OF PATIENT REPORTED SIDE-EFFECTS FOR CAR-T VERSUS OTHER THERAPIES IN PATIENTS WITH RELAPSED LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - AN ANALYSIS FROM THE LYMPHOMA COALITION'S 2024 GLOBAL PATIENT SURVEY

Natacha Bolaños (Spain)

CARE-T: THE CAREGIVER'S PERSPECTIVE - AN EVALUATION OF SELF-PERCEIVED BURDEN AND IMPACT AMONGST CAREGIVERS OF CAR-T PATIENTS

Roberto Liu (The Netherlands)

What is shared decision making and why should we care

Jennifer Vidrine (United Kingdom)

Panel discussion

All speakers

Day 3: Saturday, February 8, 2025

International session - 08:30 - 09:30Room Schweitzer

Chairs: Nico Gagelmann (Germany) & Koray Yalcin (Türkiye)

Slovenia

Matjaz Sever (Slovenia)

Academic CAR T-cell Production in Türkiye

Siret Ratip (Türkiye)

India

Rahul Purwar (India)

CAR T cells in Brazil

Nelson Hamerschlak (Brazil)

Panel discussion

All speakers

Myeloma - 08:30 - 09:30Room Cassin

Chairs: Sonja Zweegman (The Netherlands) & Hermann Einsele (Germany)

Special speaker

Jennifer Brudno (United States)

Academic CART-cells

Carlos Fernández de Larrea (Spain)

Commercial CART-cells

Vladan Vucinic (Germany)

Bispecifics

Niels van de Donk (The Netherlands)

Optimizing Long Term Outcome of patients with B-cell lymphomas - 09:45 - 11:15Room Schweitzer

Chair: Natacha Bolaños (Spain) & Annalisa Ruggeri (Italy)

Long term outcome of CART cell therapy in patients with B-cell lymphomas (DLBCL, MCL, FL)

Andrea KuhnI (United Kingdom)

Sequencing therapies

Gloria Iacoboni (Spain)

Treatment after relapse

Emmanuel Bachy (France)

Optimized constructs and the potential of sequential CARs in LBCL

Anne Marijn Kramer (United States)

Panel discussion

All speakers

Coffee break - 11:15 - 11:30

Keynote lecture 4 - 11:30 - 12:00Room Schweitzer

Chairs: Ulrike Köhl (Germany)

Keynote Lecture: CARs, TRUCKs, and what is next?

Hinrich Abken (Germany)

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)

**MICROBIOME-DERIVED METABOLITES GUIDE PATIENT OUTCOME PREDICTION AND CAR-T CELL ENGINEERING**  
Maik Luu (Germany)

**PATIENT REPORTED OUTCOMES OF CAR-T CELL THERAPY: A EUROPEAN STUDY EVALUATING PATIENTS' EXPERIENCES, QUALITY OF LIFE AND UNMET CARE NEEDS - ZOOMING IN ON SOCIAL WELLBEING**  
Elise Pennings (The Netherlands)

**FEASIBILITY OF A DECENTRALIZED ACADEMIC POINT-OF-CARE NETWORK FOR CAR-T CELL THERAPY**  
Mireia Bachiller (Spain)

**GENERATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING P95HER2 IN SOLID TUMORS**  
Macarena Román Alonso (Spain)

**A MULTICENTER TRIAL OF VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) FOR ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (CART19-BE-02 TRIAL)**  
Valentin Ortiz-Maldonado (Spain)